Sunvozertinib
Generic Name: sunvozertinib
Manufactured by DIZAL JIANGSU. Dosage form: TABLET. Route: ORAL. Active ingredients: SUNVOZERTINIB (150MG). Application: NDA219839.
Overview
Manufactured by DIZAL JIANGSU. Dosage form: TABLET. Route: ORAL. Active ingredients: SUNVOZERTINIB (150MG). Application: NDA219839.
Dosage
Available as tablet for oral use.
Related Medications
Lapyrium Chloride
lapyrium chloride
Manufactured by CHESEBROUGH PONDS. Dosage form: SOLUTION. Route: TOPICAL. Active ingredients: LAPYRIUM CHLORIDE (0.5%); UNDECOYLIUM CHLORIDE IODINE COMPLEX (1.8%). Application: NDA011914.
Codeine Phosphate, Dexbrompheniramine Maleate
codeine phosphate, dexbrompheniramine maleate
Antihistamine Antitussive
Anti-inhibitor Coagulant Complex
anti-inhibitor coagulant complex
11 DESCRIPTION FEIBA (Anti-Inhibitor Coagulant Complex) is a freeze-dried sterile human plasma fraction with factor VIII inhibitor bypassing activity to be reconstituted for intravenous administration. Factor VIII inhibitor bypassing activity is expressed in arbitrary units. One unit of activity is defined as that amount of FEIBA that shortens the aPTT of high titer factor VIII inhibitor reference plasma to 50% of the blank value.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.